{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:40:00Z","timestamp":1794663600884,"version":"4.9.1"},"reference-count":19,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Therapies that demonstrate durable, long-term responses with manageable safety and tolerability are needed for patients with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL). Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]), an anti-CD19 antibody conjugated to a potent pyrrolobenzodiazepine dimer, demonstrated single-agent antitumor activity in the pivotal phase II LOTIS-2 study in heavily pretreated patients with R\/R DLBCL. Here we present updated efficacy and safety analyses from LOTIS-2, performed for all patients and in subsets of patients with a complete response (CR), including patients with CR who were event-free (no progressive disease or death) for \u22651 year and \u22652 years from cycle 1, day 1 of treatment. Lonca was administered every 3 weeks (0.15 mg\/kg for 2 cycles; 0.075 mg\/kg for subsequent cycles). As of the final data cutoff (September 15, 2022; median follow-up: 7.8 months [range, 0.3-42.6]), 70 of 145 (48.3%) patients achieved an overall response. Thirty-six (24.8%) patients achieved CR, of which 16 (44%) and 11 (31%) were event-free for \u22651 year and \u22652 years, respectively. In the all-treated population, the median overall survival was 9.5 months; the median progression-free survival was 4.9 months. Among patients with CR, median overall survival and progression-free survival were not reached, with 24-month overall and progression-free survival rates of 68.2% (95% CI: 50.0-81.0) and 72.5% (95% CI: 48.2-86.8), respectively. No new safety concerns were detected. With additional follow-up, Lonca continued to demonstrate durable, long-term responses with manageable safety and tolerability in patients with CR (clinicaltrials gov. Identifier: NCT03589469).<\/jats:p>","DOI":"10.3324\/haematol.2023.283459","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:12:49Z","timestamp":1693411969000},"page":"1184-1193","source":"Crossref","is-referenced-by-count":34,"title":["Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study"],"prefix":"10.3324","volume":"109","author":[{"given":"Paolo F.","family":"Caimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Alderuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirit M.","family":"Ardeshna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying Cindy","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"59723","doi-asserted-by":"crossref","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014; 32(10):1066-1073.","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"59724","doi-asserted-by":"crossref","unstructured":"Crump M, Neelapu SS, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"59725","doi-asserted-by":"crossref","unstructured":"Chow VA, Gopal AK, Maloney DG. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol. 2019; 94(8):E209-E213.","DOI":"10.1002\/ajh.25505"},{"key":"59726","doi-asserted-by":"crossref","unstructured":"Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?. Blood. 2022; 139(18):2737-2746.","DOI":"10.1182\/blood.2022015789"},{"key":"59727","doi-asserted-by":"crossref","unstructured":"Kansagra A, Farnia S, Majhail N. Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2020; 40:1-8.","DOI":"10.1200\/EDBK_279151"},{"key":"59728","doi-asserted-by":"crossref","unstructured":"Zammarchi F, Corbett S, Adams L. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018; 131(10):1094-1105.","DOI":"10.1182\/blood-2017-10-813493"},{"key":"59729","doi-asserted-by":"crossref","unstructured":"Hartley JA, Flynn MJ, Bingham JP. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep. 2018; 8(1):10479.","DOI":"10.1038\/s41598-018-28533-4"},{"key":"59730","unstructured":"ADC Therapeutics. ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) [package insert]. 2023. Publisher Full Text|"},{"key":"59731","unstructured":"European Medicines Agency. Zynlonta Product Information. 2023. Publisher Full Text|"},{"key":"59732","doi-asserted-by":"crossref","unstructured":"Caimi PF, Ai W, Alderuccio JP. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021; 22(6):790-800.","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"59733","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Carlo-Stella C, Ai W. LOTIS-2 follow-up analysis: updated results from a phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma. Hematol Oncol. 2021; 39(S2):252.","DOI":"10.1002\/hon.89_2880"},{"key":"59734","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"59735","doi-asserted-by":"crossref","unstructured":"Smith SK, Zimmerman S, Williams CS, Zebrack BJ. Health status and quality of life among non-Hodgkin lymphoma survivors. Cancer. 2009; 115(14):3312-3323.","DOI":"10.1002\/cncr.24391"},{"key":"59736","doi-asserted-by":"crossref","unstructured":"Caimi PF, Hamadani M, Carlo-Stella C. CD19 expression by IHC alone is not a predictor of response to loncastuximab tesirine: results from the LOTIS-2 clinical trial and quantitative systems pharmacology modeling. Blood. 2022; 140(Supplement 1):9548-9550.","DOI":"10.1182\/blood-2022-159626"},{"key":"59737","doi-asserted-by":"crossref","unstructured":"Caimi PF, Ardeshna KM, Reid E. The antiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after antiCD19 CAR-T cell therapy. Clin Lymphoma Myeloma Leuk. 2022; 22(5):e335-e339.","DOI":"10.1016\/j.clml.2021.11.005"},{"key":"59738","doi-asserted-by":"crossref","unstructured":"Hartley JA. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther. 2021; 21(7):931-943.","DOI":"10.1080\/14712598.2020.1776255"},{"key":"59739","doi-asserted-by":"crossref","unstructured":"Lee TH, Kim WR, Poterucha JJ. Evaluation of elevated liver enzymes. Clin Liver Dis. 2012; 16(2):183-198.","DOI":"10.1016\/j.cld.2012.03.006"},{"key":"59740","doi-asserted-by":"crossref","unstructured":"Xie J, Wu A, Liao L. Characteristics and treatment patterns of relapsed\/refractory diffuse large B-cell lymphoma in patients receiving \u22653 therapy lines in post-CAR-T era. Curr Med Res Opin. 2021; 37(10):1789-1798.","DOI":"10.1080\/03007995.2021.1957806"},{"key":"59741","doi-asserted-by":"crossref","unstructured":"Hamadani M, Liao L, Yang T, Chen L, Moskowitz C. Characteristics and clinical outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma who received at least 3 lines of therapies. Clin Lymphoma Myeloma Leuk. 2022; 22(6):373-381.","DOI":"10.1016\/j.clml.2021.11.011"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283459\/76022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283459\/76786","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11243\/76022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:44Z","timestamp":1794045884000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283459","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}